Cyrano Therapeutics' CYR-064 Phase 2 FLAVOR Trial Results to Be Featured at American Rhinologic Society Annual Meeting
Key Insights
Cyrano Therapeutics (search) announced that Phase 2 FLAVOR trial results for CYR-064 will be presented at the 72nd Annual Meeting of the American Rhinologic Society in Los Angeles, October 15-17, 2026.
The abstract was selected for the first presentation slot in the "Oral Presentations: Top 5 Clinical Science" track on October 16, underscoring its scientific significance.
CYR-064 is a patent-protected intranasal theophylline formulation designed as a broad-spectrum phosphodiesterase (search) inhibitor to enhance olfactory neuron excitability and restore smell.
Cyrano Therapeutics (search), a clinical-stage regenerative medicine company, announced that results from its Phase 2 FLAVOR clinical trial evaluating CYR-064 for persistent post-viral loss of smell will be featured in an oral presentation at the 72nd Annual Meeting of the American Rhinologic Society (ARS). The meeting is scheduled for October 15-17, 2026, in Los Angeles, California.
The FLAVOR trial abstract has been awarded the first presentation slot of the ARS General Session on October 16 and will lead the "Oral Presentations: Top 5 Clinical Science" track, a distinction that highlights the scientific community's interest in this investigational therapy.
Trial Design and Therapeutic Approach
The presentation, titled "FLAVOR phase 2 RCT: Theophylline nasal spray for persistent post-viral hyposmia (search)," will be delivered by Masayoshi Takashima, MD, FARS, who served as Principal Investigator of the FLAVOR trial. The study was conducted as a Phase 2 randomized, double-blind, placebo-controlled trial across 14 clinical sites in the United States, evaluating CYR-064 in patients suffering from persistent post-viral loss of smell.
CYR-064 is a patent-protected, intranasal formulation of a broad-spectrum phosphodiesterase (search) (PDE) inhibitor. The therapy employs a patent-protected targeted delivery system designed to enhance olfactory neuron excitability and restore the sense of smell. The active pharmaceutical ingredient is theophylline, delivered via nasal spray.
Unmet Need and Clinical Significance
Persistent post-viral hyposmia (search) represents a significant unmet medical need, particularly in the wake of widespread viral infections that can damage the olfactory system. Currently, there are limited therapeutic options available for patients who experience prolonged loss of smell following viral illness.
"We are honored to have the FLAVOR Phase 2 data selected for an oral presentation in the Top 5 Clinical Science track at the American Rhinologic Society's Annual Meeting," said Rick Geoffrion, President and CEO of Cyrano Therapeutics (search). "ARS is widely regarded as the premier scientific meeting for physicians and researchers focused on rhinologic and olfactory disorders, and we look forward to sharing our findings with leaders in the field."
Geoffrion added, "We believe CYR-064 has the potential to address a significant unmet need for patients suffering from persistent post-viral loss of smell, and this presentation represents an important opportunity to advance awareness of both the condition and our therapeutic approach."
Company Background
Cyrano Therapeutics (search) is a private, venture-backed clinical-stage regenerative medicine company focused on developing therapies for individuals struggling with the loss of smell and taste. The company has been working since its foundation to advance treatments in this underserved therapeutic area.